Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > H2s Covid

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Feb 10, 2021 9:13am

129 Views

Post# 32523238

RE:RE:RE:H2s Covid

That's the unfortunate thing ... we don't have enough info.

But ... if it's about ATB-340 or Aspirin with a new delivery molecule (20 year patent) then it may have purpose as a COVID therapeutic. Maybe a general viral therapeutic.

With some luck, I'm thinking it could fast-track and leapfrog OTENA to market.

Just saying ... until we know more ... there's hope.

: )

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth